Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$2.08 USD
-0.22 (-9.57%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $2.10 +0.02 (0.96%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Verrica Pharmaceuticals Inc. (VRCA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.00 | $18.00 | $12.00 | 508.70% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Verrica Pharmaceuticals Inc. comes to $14.00. The forecasts range from a low of $12.00 to a high of $18.00. The average price target represents an increase of 508.7% from the last closing price of $2.30.
Analyst Price Targets (6 )
Broker Rating
Verrica Pharmaceuticals Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VRCA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
8/15/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/15/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
8/14/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Strong Buy |
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $14.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 99 of 253 |
Current Quarter EPS Est: | -0.36 |